No black box warning on record for Winrevair

As of the latest FDA labeling reviewed, Winrevair (SOTATERCEPT-CSRK) does not carry a black box warning. Standard warnings and precautions still apply — see the full Winrevair medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Erythrocytosis: If severe, may increase the risk of thromboembolic events and hyperviscosity syndrome. Monitor Hgb before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter to determine if dose adjustments are required. ( 5.1 ) Severe Thrombocytopenia: May increase the risk of bleeding. Monitor platelets before each dose for th

No black box warning on record for Winrevair

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Erythrocytosis: If severe, may increase the risk of thromboembolic events and hyperviscosity syndrome. Monitor Hgb before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter to determine if dose adjustments are required. ( 5.1 ) Severe Thrombocytopenia: May increase the risk of bleeding. Monitor platelets before each dose for th

Winrevair Black Box Warning

No black box warning on record for Winrevair

Other warnings & precautions

Winrevair Black Box Warning

No black box warning on record for Winrevair

Other warnings & precautions